Group 1 - UBS downgraded the rating of Giant Bio (02367) from "Buy" to "Neutral" due to increased uncertainty in short-term revenue and profit outlook [1] - The profit forecast for 2025 to 2027 was cut by 25% to 41%, with revenue projections reduced by 20% to 36% during the same period [1] - The target price was significantly lowered from HKD 79.5 to HKD 39.5 [1] Group 2 - The report indicates intensified market competition, with the emergence of other skincare brands or products that offer more attractive pricing while also focusing on collagen restructuring [1] - Despite rapid product innovation, there is uncertainty regarding the success of new products in the coming year [1] - Maintaining high profitability is expected to be challenging in the context of increased competition and weakened marketing efficiency, with a projected erosion of 2 to 3 percentage points in net profit margin due to reduced marketing efficiency and operational deleveraging [1]

Core Viewpoint - UBS downgraded the rating of Giant Bio (02367) from "Buy" to "Neutral" due to increased uncertainty in short-term revenue and profit outlook [1] Financial Projections - UBS reduced the earnings forecast for 2025 to 2027 by 25% to 41% [1] - Revenue projections for the same period were lowered by 20% to 36% [1] - Target price was significantly cut from HKD 79.5 to HKD 39.5 [1] Market Competition - The current market is experiencing intensified competition with the emergence of other skincare brands or products that offer more attractive pricing while also focusing on collagen restructuring [1] - Despite rapid product innovation, there is uncertainty regarding the success of new products in the coming year [1] Profitability Challenges - Maintaining high profitability is expected to be challenging in the context of increased competition and weakened marketing efficiency [1] - UBS anticipates a 2 to 3 percentage point erosion in net profit margin due to reduced marketing efficiency and operational deleveraging [1]